Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study

Abstract

Objective

To assess the risk of all-cause mortality and major adverse cardiovascular events (MACE) in patients with immune-mediated inflammatory diseases (IMIDs) and type 2 diabetes newly initiating glucagon-like peptide-1 receptor agonists (GLP-1-RAs) versus dipeptidyl peptidase-4 inhibitors (DPP-4is).

Methods

We performed a population-based cohort study using administrative health data from British Columbia. Patients with an IMID (i.e., rheumatoid arthritis, psoriatic disease, ankylosing spondylitis, inflammatory bowel disease, or a systemic autoimmune rheumatic disease) and type 2 diabetes who newly initiated a GLP-1-RA or DPP-4i between January 1, 2010, and December 31, 2021 were identified using ICD-9/10 codes. The primary outcome was all-cause mortality. Secondary outcomes included MACE and its components (i.e., cardiovascular death, myocardial infarction, and ischemic stroke). Cox proportional hazard regressions were used with propensity score overlap weighting. The analysis was repeated in age- and sex-matched adults without IMIDs.

Results

We identified 10,855 adults with IMIDs and type 2 diabetes who newly initiated a GLP-1-RA or DPP-4i. All-cause mortality rate was lower among initiators of GLP-1-RAs compared to initiators of DPP-4is, with a weighted hazard ratio (HR) of 0.48 (95% confidence interval [CI], 0.31–0.75) and rate difference (RD) of -9.4 (95% CI, -16.0 to -2.7) per 1000 person-years. Rate of MACE was also lower with GLP-1-RA exposure (HR 0.66 [0.50–0.88], RD -10.5 [-20.4 to -0.8]). Effect sizes were similar in adults without IMIDs.

Conclusion

In patients with IMIDs and type 2 diabetes, GLP-1-RA exposure is associated with a lower risk of all-cause mortality and MACE compared to a cardioneutral active comparator.

Introduction

Risk of cardiovascular mortality is significantly increased in many immune-mediated inflammatory diseases (IMIDs), including rheumatoid arthritis (RA) [1], psoriasis [2], ankylosing spondylitis (AS) [3], systemic lupus erythematosus (SLE) [4], ANCA-associated vasculitis (AAV) [5], and giant cell arteritis (GCA) [6]. Cardiac risk factors such as type 2 diabetes and obesity are common, well-described states of chronic low-grade inflammation that can affect the severity of underlying IMIDs [7–10]. Moreover, chronic inflammation (which may arise from autoimmune diseases or obesity) plays a key role in the pathogenesis of insulin resistance, β-cell dysfunction, and accelerated atherogenesis, highlighting a common link between autoimmunity, obesity, diabetes, and atherosclerosis [10–12]. Chronic low-grade inflammatory states arising from the interplay of one or more of these four entities may predispose affected individuals to higher rates of major adverse cardiovascular events (MACE) and premature mortality. As a result, therapies that inhibit key cytokines and pro-inflammatory pathways are being explored with aims of reducing cardiovascular risk in susceptible patients [10, 12]. In this regard, glucagon-like peptide-1 receptor agonists (GLP-1-RAs) are promising agents.

Approved for the management of type 2 diabetes and obesity, GLP-1-RAs were shown in a 2021 Cochrane meta-analysis and systematic review to reduce the risk of all-cause mortality, cardiovascular mortality, and stroke [13]. However, none of the included randomized controlled trials (RCTs) reported the effects on patients with IMIDs [13]: two studies excluded patients on systemic corticosteroids [14, 15] and one excluded patients with inflammatory bowel disease (IBD) [16]. Therefore, a gap exists in understanding whether GLP-1-RAs have similar cardioprotective effects in patients with IMIDs, who have a higher risk of cardiovascular complications due to chronic inflammation associated with their underlying condition. A scoping review on the effects of GLP-1-RAs in inflammatory arthritis and psoriasis revealed that these agents have anti-inflammatory properties through inhibition of the NF-κB pathway; however, how these effects translate clinically is limited to case reports, small uncontrolled prospective cohorts, and two small RCTs in psoriasis with conflicting results [17].

Dipeptidyl peptidase-4 inhibitors (DPP-4is) are anti-diabetic agents similar to GLP-1-RAs in that both drug classes increase GLP-1 receptor signalling [18] and were third line in British Columbia until January 2023 (at which point GLP-1-RAs became second line) [19]. While GLP-1-RAs directly stimulate the GLP-1 receptor, DPP-4is prevent breakdown of endogenous GLP-1. DPP-4is cause more modest reductions in A1c and neither induce significant weight loss nor reduce the risk of stroke or mortality [13].

We hypothesized that GLP-1-RAs may be cardioprotective for patients with IMIDs, and that patients with IMIDs (because of elevated cardiovascular risk due to chronic inflammation) may derive greater benefit than those without. To test these hypotheses, we compared the risk of all-cause mortality and new MACE (including cardiovascular mortality, myocardial infarction, and ischemic stroke) in adults with IMIDs and type 2 diabetes initiating a GLP-1-RA versus a DPP-4i, and then repeated this analysis in age- and sex-matched adults without IMIDs to compare the effect sizes.

Materials and methods

Source population and data

Our source population was the entire population of British Columbia (BC), Canada. Universal healthcare coverage is available for all BC residents (population ~5.2 million in 2021) [20]. We used Population Data BC, which provides access to all provincially-funded healthcare services data since 1990, including de-identified individual-level data on all outpatient medical visits [21], hospital admissions and discharges [22], and emergency room (ER) visits [23]. Population Data BC also holds the comprehensive prescription drug database, PharmaNet, which contains all pharmacy-dispensed medications for all BC residents since 1996, including dose, date, and quantity dispensed [24]. Vital statistics data on cause-specific deaths were also obtained for all patients [25].

Study population and design

We performed a sequential propensity score (PS) overlap weighted cohort study to compare risk of all-cause mortality and MACE in new users of GLP-1-RAs or DPP-4is with IMIDs and type 2 diabetes. All GLP-1-RAs and DPP-4is approved in Canada were included (S1 Table). We included patients ≥18 years old who had an IMID (e.g., RA, psoriatic disease, AS, IBD, or a systemic autoimmune rheumatic disease [SARD] such as SLE, systemic sclerosis, Sjögren’s disease, autoimmune inflammatory myositis, GCA, AAV, Takayasu’s arteritis, and polyarteritis nodosa) and type 2 diabetes from January 1, 2010, to December 31, 2021, with at least two years of continuous enrollment in Population Data BC prior to entering the study. The diagnoses of IMID and type 2 diabetes were based on the presence of at least two physician-diagnosed International Classification of Diseases, Ninth or 10^th Revision (ICD-9 or ICD-10) codes (S2 Table) at least two months apart within a 2-year window for the IMID (i.e., RA, psoriatic disease, AS, IBD, or SARD) or type 2 diabetes, respectively. Case definitions for these diseases have been shown to have specificities >90% and positive predictive values between 78 and 98% in validation studies [26–30]. Our definition of psoriatic disease encompasses both psoriasis and psoriatic arthritis given the limitations of administrative data in distinguishing the two entities. Of this IMID with diabetes cohort, we identified patients whose first-ever dispensing for a GLP-1-RA or DPP-4i occurred after the diagnosis of these two diseases. The date of the first dispensing of either agent was defined as the index date. Individuals were excluded if they had been prescribed either drug class any time before the index date.

Cohort follow-up

Follow-up began at the index date and continued until the end of the study period, end of continuous health plan enrollment, occurrence of a study outcome, or discontinuation of the initial medication (or switching to or addition of the comparator medication), whichever occurred first. A medication was considered discontinued if 60 days elapsed after the expiration date of the last prescription’s supply without a refill.

Outcome assessment

The primary outcome was all-cause mortality (identified by death date). Secondary outcomes included MACE and its components (i.e., cardiovascular death [from any cardiac cause, defined by death date plus ICD-9 codes 390–459 or ICD-10 codes I00-I99], myocardial infarction [MI, defined by new codes of 410 or I21], and ischemic stroke [defined by new codes of 433, 434, I63, I64, I65, or I66]). Diagnostic codes for MI and ischemic stroke have high validity in administrative data with most studies yielding PPVs of ≥93% and ≥82%, respectively [31, 32].

Covariate assessment

Covariates included sociodemographic factors (age, sex, neighborhood income quintile [measure of area-level socioeconomic status], and health authority region), comorbidities at any time from enrollment to the index date based on ICD-9 or ICD-10 codes (obesity, hypertension, MI, stroke, transient ischemic attack, congestive heart failure, ischemic heart disease, varicose veins, venous thromboembolism, chronic kidney disease, cancer, infection, and chronic obstructive pulmonary disease), diabetes-related complications (diabetic nephropathy, neuropathy, or retinopathy, and hospitalizations due to diabetes), modified Charlson Comorbidity Index for administrative data [33], medication use (other antidiabetic medications, immunosuppressives [biologics, corticosteroids, other oral and subcutaneous agents], cardiovascular medications [aspirin, statins, fibrates, diuretics, other], proton pump inhibitors, colchicine, urate-lowering therapy, opioids, non-steroidal anti-inflammatory drugs, and anticoagulants), and healthcare utilization (hospitalizations and ER visits) in the 12 months before the index date (Table 1). Diabetes and IMID duration were also included, where date of diagnosis was defined by first ICD-9/10 code (Table 1).

[Figure omitted. See PDF.]

Statistical analysis

We divided calendar time into one-year blocks from 2010 (when GLP-1-RAs entered the Canadian market [34]) to 2021 (i.e., 12 blocks). Participants were allocated into one of 12 blocks based on the date they initiated a study drug. For example, participants whose initiation date fell between January 1, 2010, and December 31, 2010 would be allocated into the first time block (year 2010). Within each time block, we assembled a cohort of GLP-1-RA initiators (defined as patients who started a GLP-1-RA during that time block) and a cohort of comparator initiators who started a DPP-4i during the same time block. In each yearly time block, we calculated PS of treatment assignment (e.g., GLP-1-RA initiation) conditional on observed baseline characteristics described above and applied overlap weighting of the PS to balance baseline characteristics between the comparison groups [35]. Overlap weighting overcomes common limitations of classic PS methods by down-weighting patients at the extremes of the PS distribution rather than excluding them, improving balance and precision without sacrificing sample size [35, 36]. Individuals initiating a GLP-1-RA were weighted by the probability of not initiating a GLP-1-RA, i.e., 1-PS, and individuals initiating a DPP-4i were weighted by the probability of initiating a GLP-1-RA, i.e., PS. We assessed the balance of the distribution of baseline characteristics before and after overlap weighting by calculating the absolute standardized mean differences [37]. We calculated the weighted incidence rate (IR) for each outcome and estimated the weighted absolute rate difference (RD) between the comparison groups. We performed a Cox proportional hazard model to obtain hazard ratios (HR) and 95% confidence intervals (CI) estimating the risk for each outcome. Death was considered as the competing risk in the regression model when assessing MI and stroke as outcomes [38]. We calculated an E-value to assess the robustness of our primary outcome to unmeasured confounders [39]. Data analysis on subpopulations (e.g., RA with diabetes) were also separately conducted to assess for consistency across IMIDs.

Pre-defined sensitivity analyses excluding patients with prior MI or ischemic stroke, excluding those who discontinued either drug class within 3 months of initiation, and applying an intention-to-treat approach (following patients until the end of the study period, end of continuous health plan enrollment, or occurrence of a study outcome, whichever occurred first) were performed. Lastly, we evaluated risk of herpes zoster reactivation as a negative control outcome, expecting no difference in risk between exposure groups.

To evaluate whether patients with IMIDs derived greater benefit than those without, we assembled two additional diabetic cohorts of GLP-1-RA or DPP-4i initiators without IMIDs who were strata matched to our primary cohorts based on age, sex, and index date, and then we repeated our analysis in this non-IMID population.

All P values were 2-sided and P<0.05 was considered significant for all tests. All statistical analyses were performed with SAS software, version 9.4 (SAS Institute, Cary, North Carolina, USA).

No patients were involved in the design or conduct of this study. Ethics approval was obtained from the University of British Columbia’s Behavioral Research Ethics Board (H15-00887). This study followed the recommendations of the STROBE initiative for reporting observational studies in epidemiology [40].

Results

Of the 10,855 patients included, 3,570 formed the GLP-1-RA cohort and 7,285 formed the DPP-4i comparison cohort; demographic and clinical characteristics are shown in Table 1. Before PS overlap weighting, patients initiating GLP-1-RAs had higher rates of diabetic neuropathy and obesity, as well as higher prevalence of insulin, sodium-glucose cotransporter-2 inhibitor, and biologic prescriptions. Patients initiating DPP-4is were older, more often male, and had higher prevalence of metformin and sulfonylurea prescriptions. They also had higher rates of diabetic nephropathy and retinopathy, plus higher mean Charlson Comorbidity Index and healthcare utilization. Weighted mean follow up was 1.46 and 1.88 years in GLP-1-RA and DPP-4i cohorts, respectively.

After PS weighting, the baseline characteristics between the two matched cohorts were well-balanced, with all standardized differences less than 0.10 (Table 1). The mean age was 60.67 years and the most common IMIDs were psoriatic disease (42.4%) and RA (37.5%).

All-cause mortality

Overall, there were 28 deaths among 3,570 patients with IMIDs and type 2 diabetes initiating a GLP-1-RA (8.5 per 1,000 person-years) compared to 446 deaths among 7,285 patients initiating a DPP-4i (17.9 per 1,000 person-years), yielding a weighted HR of 0.48 (CI 0.31–0.75) and RD of -9.4 (CI -16.0 to -2.7) per 1,000 person-years for all-cause mortality (Table 2). Cumulative mortality rate is presented in Fig 1A. Similar trends were observed when limiting to patients with RA or psoriatic disease (S3 and S4 Tables). In the RA-diabetes subgroup, there were 15 deaths among 1,367 new users of GLP-1-RAs compared to 219 deaths among 2,913 new users of DPP-4i (weighted IR: 9.3 versus 20.9 deaths per 1,000 person-years; HR: 0.45 [0.22–0.93], RD: -11.6 [-26.3 to 3.0]). In psoriatic disease, a trend toward reduced all-cause mortality existed, but it was not statistically significant (HR: 0.54 [0.25–1.19]). Due to small sample sizes limiting power, analysis of other subpopulations did not produce stable estimates and are therefore not reported.

[Figure omitted. See PDF.]

Cumulative rate of mortality (A) and MACE (B) among new users of GLP-1-RAs versus DPP-4is with IMIDs. MACE, major adverse cardiovascular events; IMID, immune-mediated inflammatory disease, GLP-1-RA, glucagon-like peptide-1 receptor agonist; DPP-4i, dipeptidyl peptidase-4 inhibitor.

[Figure omitted. See PDF.]

In sensitivity analyses, risk of all-cause mortality after overlap weighting was similarly lower with GLP-1-RA exposure when patients with prior MI or ischemic stroke were excluded (HR 0.42 [0.24–0.75], RD -8.5 [-14.9 to -2.0]), when patients who discontinued therapy within 3 months of initiation were excluded (HR 0.46 [0.28–0.75], RD -8.6 [-14.8 to -2.0]), and when an intention-to-treat approach (where follow up was 4.92 and 4.82 years in GLP-1-RA- and DPP-4i-exposed groups, respectively) was employed (HR 0.72 [0.60–0.86], RD -6.8 [-11.7 to -1.9]).

Major adverse cardiovascular events

There were 83 MACE among 3,570 patients with IMIDs and type 2 diabetes initiating a GLP-1-RA (21.5 per 1,000 person-years) compared to 632 MACE among 7,285 patients initiating a DPP-4i (32.0 per 1,000 person-years). The risk of MACE was lower in new users of GLP-1-RAs compared to new users of DPP-4is (weighted HR of 0.66 [0.50–0.88], RD of -10.5 [-20.4 to -0.8] per 1,000 person-years) (Table 2). Cumulative rate of MACE is presented in Fig 1B. Weighted HRs were 0.62 (0.40–0.96) for MI, 0.53 (0.20–1.40) for cardiovascular death, and 0.74 (0.50–1.11) for ischemic stroke (Table 2). In subgroup analyses limited to patients with RA or psoriatic disease, a signal towards lower incidence of MACE was similarly observed, but this only reached statistical significance in RA (S3 and S4 Tables). In the RA-diabetes subgroup, weighted IRs for MACE in new users of GLP-1-RAs and DPP-4is were 16.2 and 40.4 per 1,000 person-years, respectively, corresponding to a HR of 0.39 (0.22–0.69) and a RD of -24.2 (-43.7 to -4.7).

Sensitivity analysis excluding patients who discontinued therapy within 3 months of initiation also illustrated a significant risk reduction (weighted HR: 0.69 [0.50–0.96]; RD: -8.5 [-17.0 to -0.1]), as did the analysis employing an intention-to-treat approach (weighted HR: 0.80 [0.69–0.94]; RD -6.4 [-12.4 to -0.4]). Sensitivity analysis excluding patients with prior MI or ischemic stroke showed fewer MACE with GLP-1-RA exposure, but this did not reach statistical significance (weighted HR: 0.72 [0.49–1.05]; RD: -7.0 [-16.1 to 2.2]).

Outcomes in patients with and without IMIDs

Similar risk reductions in mortality and MACE were observed among patients without IMIDs initiating GLP-1-RAs versus DPP-4is in both per protocol and intention-to-treat analyses (S5 Table). Confidence intervals overlapped, indicating that effect sizes were not significantly different comparing populations with and without IMIDs. Per protocol and intention-to-treat analyses in patients without IMIDs estimated HRs of 0.34 [0.26–0.44] and 0.69 [0.63–0.76] for all-cause mortality, and 0.7 [0.6–0.8] and 0.88 [0.81–0.95] for MACE, respectively.

Potential impact of unmeasured confounding

The E-value for our primary outcome of all-cause mortality with GLP-1-RA versus DPP-4i exposure was 3.59 (CI 2.00 to 5.91), indicating that an unmeasured confounder would need to be associated with both GLP-1-RA use and all-cause mortality by a risk ratio of 3.59 to nullify our findings.

Control outcomes

There was no difference in herpes zoster reactivation between the two exposure groups (weighted IRs of 11.1 and 11.7 per 1,000 person-years for GLP-1-RA and DPP-4i initiators, respectively; HR 0.96 [0.65–1.43]; RD -0.6 [-1.5 to 0.3]).

Discussion

In this large population-based cohort study comparing risk of all-cause mortality and MACE in new users of GLP-1-RAs or DPP-4is with IMIDs and type 2 diabetes, we found a 52% relative risk reduction in all-cause mortality and 34% relative risk reduction in MACE with GLP-1-RA exposure. This corresponds to nine fewer deaths and 11 fewer MACE per 1,000 person-years, respectively, supporting the hypothesis that these agents have a cardioprotective effect in this high-risk population. While insufficient power limited the number of subgroup analyses, results were directionally consistent for RA and psoriatic disease alone (each comprising about 40% of the cohort). Effect sizes were similar when compared to matched controls without IMIDs.

Elevated cardiovascular risk has been well-described in the majority of IMIDs included in this study [1–6]. While GLP-1-RAs have been shown to reduce mortality and major adverse cardiovascular events across several RCTs, patients with IMIDs have either been excluded or not reported on in these trials [13–16]. Our results fill this existing gap and suggest that GLP-1-RAs have a similar protective effect on all-cause mortality and cardiovascular morbidity in patients with IMIDs, a previously understudied but high-risk population. As DPP-4is have not been found to increase risk of death or MACE in the general population [13], we suspect our results are more likely due to GLP-1-RA-related benefit as opposed to DPP-4i-related harm. While we hypothesized that patients with IMIDs may derive greater benefit from GLP-1-RAs than the general population because of their higher baseline cardiovascular risk, this was not the case based on our data. While effect sizes in our study were larger than what has been reported in prior RCTs [13] (potentially owing to differences in study populations lending a more conservative estimate in RCTs, as well as a degree of possible unmeasured confounding in our study), they were similar between groups with and without IMIDs.

Beyond glycemic control, GLP-1-RAs may offer benefit for patients with various IMIDs through weight loss and possible adiposity-independent anti-inflammatory effects. Obesity is an inflammatory state impacting disease activity and response to therapy in several IMIDs [7]. Higher disease activity is associated with higher cardiovascular risk [41]. We therefore hypothesize that the observed reduced cardiovascular risk may be in part due to reduced adiposity leading to decreased adipokine-mediated inflammation. Clinically, whether weight loss through GLP-1 receptor agonism improves disease activity in patients with obesity and IMIDs warrants further study.

Mechanisms independent of weight loss may be at play in explaining the observed results. Basic science studies in RA, psoriasis, and IBD have demonstrated weight-independent anti-inflammatory effects of GLP-1-RAs [42–46]. One commonly described mechanism across all three diseases is GLP-1-RA-mediated inhibition of the NF-κB pathway. These agents have been found to prevent phosphorylation and breakdown of IκBα (a key inhibitory protein) in RA [43, 44, 47] and promote phosphorylation of AMPK in psoriasis (which indirectly prevents p65 nuclear translocation) [45, 48]. The role of the NF-κB pathway in atherogenesis and cardiovascular diseases is complex and remains an area of active research [49]; studies are needed to determine whether downregulation of this pathway may contribute to the lower associated risks of all-cause mortality and MACE observed in this study.

Our study has several limitations. There were imbalances in baseline covariates between the two comparison groups; however, propensity score overlap weighting was applied to address the potential confounding effect of these imbalances. After overlap weighting, new users of GLP-1-RAs and DPP-4is were perfectly balanced on all observed baseline variables. That said, residual or unmeasured confounding may still have affected study results. Capture of comorbidities relies on diagnostic codes for physician billing and therefore may be incomplete, especially with regards to obesity where sensitivity of ICD-9/10 codes are <40% [50]. Roughly 22% of our cohort had a diagnosis of obesity and we suspect this represents underreporting. That said, our E-value of 3.59 indicates that, in addition to the measured covariates that were included, an unmeasured covariate (like obesity) would need to be associated with both GLP-1-RA use and all-cause mortality by a risk ratio of 3.59 to nullify our findings. This is unlikely. As patients with obesity are at increased cardiovascular risk [51] and are more likely to receive a GLP-1-RA than a DPP-4i, the bias introduced by underreporting obesity would be conservative, favoring the null hypothesis. Smoking could not be accurately captured with our database and therefore was not included as a covariate. Uncertainty around the accuracy of the case definition for each IMID cannot be ruled out, but a strict algorithm (≥2 physician-diagnosed ICD codes ≥2 months apart within a 2-year window) was used. Such algorithms have high specificity (>90%) and moderate-to-high PPV (78–98%) across several validation studies [26–30]. Finally, while mean follow up in our per protocol analysis was between 1 and 2 years, intention-to-treat analysis (where follow-up was nearly 5 years) and sensitivity analysis excluding patients who discontinued therapy within the first 3 months yielded similar results.

This study also has strengths. We used an entire population-based database, increasing generalizability, and performed additional sensitivity analyses (e.g., excluding prior MI or ischemic stroke), enhancing the robustness of our findings. We also demonstrated no difference in our negative control outcome (herpes zoster reactivation), lending specificity to the observed effects of GLP-1-RAs.

Conclusions

Findings from our population-based cohort study indicate that, compared with DPP-4i exposure, GLP-1-RA exposure is associated with a significantly lower risk of all-cause mortality and MACE in patients with IMIDs and type 2 diabetes, similar to what is observed in patients without IMIDs.

Supporting information

S1 Table. Included glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

https://doi.org/10.1371/journal.pone.0308533.s001

(DOCX)

S2 Table. Diagnostic codes used to define immune-mediated inflammatory diseases and diabetes mellitus.

https://doi.org/10.1371/journal.pone.0308533.s002

(DOCX)

S3 Table. All-cause mortality and MACE among patients with rheumatoid arthritis and type 2 diabetes initiating GLP-1-RAs or DPP-4is, after propensity score overlap weighting.

https://doi.org/10.1371/journal.pone.0308533.s003

(DOCX)

S4 Table. All-cause mortality and MACE among patients with psoriatic disease and type 2 diabetes initiating GLP-1-RAs or DPP-4is, after propensity score overlap weighting.

https://doi.org/10.1371/journal.pone.0308533.s004

(DOCX)

S5 Table. Per protocol and intention-to-treat analyses of mortality and MACE among patients without IMIDs initiating GLP-1-RAs or DPP-4is, after propensity score overlap weighting.

https://doi.org/10.1371/journal.pone.0308533.s005

(DOCX)

Acknowledgments

We would like to thank the Ministry of Health of British Columbia and Population Data BC for providing access to the administrative data. All inferences, opinions, and conclusions drawn in this publication are those of the authors, and do not reflect the opinions or policies of the Data Steward(s).

References

1. 1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Care Res 2008;59(12):1690–7. pmid:19035419

* View Article

* PubMed/NCBI

* Google Scholar

2. 2. Liu L, Cui S, Liu M, Huo X, Zhang G, Wang N. Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Front Cardiovasc Med 2022;9:829709. pmid:35402553

* View Article

* PubMed/NCBI

* Google Scholar

3. 3. Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality. Ann Intern Med 2015;163(6):409–16. pmid:26258401

* View Article

* PubMed/NCBI

* Google Scholar

4. 4. Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, et al. Mortality and Cardiovascular Burden of Systemic Lupus Erythematosus in a US Population-based Cohort. J Rheumatol 2014;41(4):680. pmid:24532834

* View Article

* PubMed/NCBI

* Google Scholar

5. 5. Wallace ZS, Fu X, Harkness T, Stone JH, Zhang Y, Choi H. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology (Oxford) 2020;59(9):2308–15. pmid:31846030

* View Article

* PubMed/NCBI

* Google Scholar

6. 6. Uddhammar A, Eriksson AL, Nyström L, Stenling R, Rantapää-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29(4):737. pmid:11950015

* View Article

* PubMed/NCBI

* Google Scholar

7. 7. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: Not a passive bystander. Autoimmun Rev 2014;13(9):981–1000. pmid:25092612

* View Article

* PubMed/NCBI

* Google Scholar

8. 8. Jiang MY, Hwang JC, Feng IJ. Impact of Diabetes Mellitus on the Risk of End-Stage Renal Disease in Patients with Systemic Lupus Erythematosus. Sci Rep 2018;8(1):6008. pmid:29662119

* View Article

* PubMed/NCBI

* Google Scholar

9. 9. Yun H, Xie F, Chen L, Yang S, Ferri L, Alemao E, et al. Evaluation of the Effect of Diabetes on Rheumatoid Arthritis–related Outcomes in an Electronic Health Record–based Rheumatology Registry. J Rheumatol 2020;48(7):992–1001. pmid:33262304

* View Article

* PubMed/NCBI

* Google Scholar

10. 10. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity 2022;55(1):31–55. pmid:35021057

* View Article

* PubMed/NCBI

* Google Scholar

11. 11. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci 2020;21(5):1835. pmid:32155866

* View Article

* PubMed/NCBI

* Google Scholar

12. 12. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol 2019;14(1):50–9. pmid:31131037

* View Article

* PubMed/NCBI

* Google Scholar

13. 13. Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021;10(10):CD013650. pmid:34693515

* View Article

* PubMed/NCBI

* Google Scholar

14. 14. Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine 2017;57(3):464–73. pmid:27830456

* View Article

* PubMed/NCBI

* Google Scholar

15. 15. Wang Q, Wang D, Cheng A, Sun FY, Li Z. Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment. Int J Clin Exp Med 2020;13(2):1219–27.

* View Article

* Google Scholar

16. 16. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19(1):69–77. pmid:27790809

* View Article

* PubMed/NCBI

* Google Scholar

17. 17. Karacabeyli D, Lacaille D. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. J Clin Rheumatol 2024;30(1):26–31. pmid:36870080

* View Article

* PubMed/NCBI

* Google Scholar

18. 18. Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol 2020;11:178. pmid:32308645

* View Article

* PubMed/NCBI

* Google Scholar

19. 19. BC Gov News. PharmaCare expands diabetes, heart failure, blood clot drugs coverage. Ministry of Health. 2023 [cited 2023 Nov 17]. Available from: https://news.gov.bc.ca/releases/2023HLTH0001-000004

* View Article

* Google Scholar

20. 20. Stats BC. 2021 Sub-Provincial Population Estimates Highlights [online]. https://www2.gov.bc.ca/assets/gov/data/statistics/people-population-community/population/pop_subprovincial_population_highlights.pdf (accessed November 24, 2022).

* View Article

* Google Scholar

21. 21. BC Ministry of Health. Medical Services Plan (MSP) Payment Information File. V2. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

22. 22. BC Ministry of Health. Discharge Abstracts Database (Hospital Separations). V2. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

23. 23. BC Ministry of Health. National Ambulatory Care Reporting System. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

24. 24. BC Ministry of Health. PharmaNet. V2. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

25. 25. BC Ministry of Health. Vital Events Deaths. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

* View Article

* Google Scholar

26. 26. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: A population study. Arthritis Rheum 2005;53(2):241–8. pmid:15818655

* View Article

* PubMed/NCBI

* Google Scholar

27. 27. Leong A, Dasgupta K, Bernatsky S, Lacaille D, Avina-Zubieta A, Rahme E. Systematic review and meta-analysis of validation studies on a diabetes case definition from health administrative records. PloS One 2013;8(10):e75256. pmid:24130696

* View Article

* PubMed/NCBI

* Google Scholar

28. 28. Arkema EV, Jönsen A, Rönnblom L, Svenungsson E, Sjöwall C, Simard JF. Case definitions in Swedish register data to identify systemic lupus erythematosus. BMJ Open 2016;6(1):e007769. pmid:26729375

* View Article

* PubMed/NCBI

* Google Scholar

29. 29. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of Inflammatory Bowel Disease With Immune Mediated Diseases Among Members of a Northern California-Managed Care Organization. Am J Gastroenterol 2007;102(7):1429–35. pmid:17437504

* View Article

* PubMed/NCBI

* Google Scholar

30. 30. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. Pharmacoepidemiol Drug Saf 2013;22(8):842–9. pmid:23637091

* View Article

* PubMed/NCBI

* Google Scholar

31. 31. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PloS One 2014;9(3):e92286. pmid:24682186

* View Article

* PubMed/NCBI

* Google Scholar

32. 32. McCormick N, Bhole V, Lacaille D, Avina-Zubieta JA. Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review. PloS One 2015;10(8):e0135834. pmid:26292280

* View Article

* PubMed/NCBI

* Google Scholar

33. 33. Romano PS, Roos LL, Jollis JG. Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46(10):1075–9.

* View Article

* Google Scholar

34. 34. Health Canada. Product Information—Victoza [Online]. 2022. Available from: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83627#fn1 (accessed 2022 Dec 14).

* View Article

* Google Scholar

35. 35. Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. Am J Epidemiol 2019;188(1):250–7. pmid:30189042

* View Article

* PubMed/NCBI

* Google Scholar

36. 36. Li F, Morgan KL, Zaslavsky AM. Balancing Covariates via Propensity Score Weighting. J Am Stat Assoc 2018;113(521):390–400.

* View Article

* Google Scholar

37. 37. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34(28):3661–79. pmid:26238958

* View Article

* PubMed/NCBI

* Google Scholar

38. 38. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999;94(446):496–509.

* View Article

* Google Scholar

39. 39. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med 2017;167(4):268–74. pmid:28693043

* View Article

* PubMed/NCBI

* Google Scholar

40. 40. Elm E von Altman DG, Egger M Pocock SJ, Gøtzsche PC Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335(7624):806. pmid:17947786

* View Article

* PubMed/NCBI

* Google Scholar

41. 41. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67(6):1449–55. pmid:25776112

* View Article

* PubMed/NCBI

* Google Scholar

42. 42. Du X, Zhang H, Zhang W, Wang Q, Wang W, Ge G, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol 2019;75:105732. pmid:31336333

* View Article

* PubMed/NCBI

* Google Scholar

43. 43. Zheng W, Pan H, Wei L, Gao F, Lin X. Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol 2019;74:105649. pmid:31185450

* View Article

* PubMed/NCBI

* Google Scholar

44. 44. Tao Y, Ge G, Wang Q, Wang W, Zhang W, Bai J, et al. Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. IUBMB Life 2019;71(7):969–77. pmid:30897288

* View Article

* PubMed/NCBI

* Google Scholar

45. 45. Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol 2019;107:124–8. pmid:30776356

* View Article

* PubMed/NCBI

* Google Scholar

46. 46. Al-Dwairi A, Alqudah TE, Al-Shboul O, Alqudah M, Mustafa AG, Alfaqih MA. Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro. J Inflamm Res 2018;11:95–109. pmid:29593427

* View Article

* PubMed/NCBI

* Google Scholar

47. 47. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017;2:17023. pmid:29158945

* View Article

* PubMed/NCBI

* Google Scholar

48. 48. Salminen A, Hyttinen JMT, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 2011;89(7):667–76. pmid:21431325

* View Article

* PubMed/NCBI

* Google Scholar

49. 49. Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. Int J Mol Sci 2019;20(7):1599. pmid:30935055

* View Article

* PubMed/NCBI

* Google Scholar

50. 50. Suissa K, Schneeweiss S, Lin KJ, Brill G, Kim SC, Patorno E. Validation of obesity-related diagnosis codes in claims data. Diabetes Obes Metab 2021;23(12):2623–31. pmid:34338404

* View Article

* PubMed/NCBI

* Google Scholar

51. 51. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021;143(21):e984–1010. pmid:33882682

* View Article

* PubMed/NCBI

* Google Scholar

Citation: Karacabeyli D, Lacaille D, Lu N, McCormick N, Xie H, Choi HK, et al. (2024) Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type 2 diabetes: A population-based study. PLoS ONE 19(8): e0308533. https://doi.org/10.1371/journal.pone.0308533

About the Authors:

Derin Karacabeyli

Roles: Conceptualization, Methodology, Writing – original draft

Affiliations: Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, Arthritis Research Canada, Vancouver, British Columbia, Canada

ORICD: https://orcid.org/0000-0002-6597-0302

Diane Lacaille

Roles: Funding acquisition, Resources, Supervision, Writing – review & editing

Affiliations: Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, Arthritis Research Canada, Vancouver, British Columbia, Canada

Na Lu

Roles: Formal analysis, Methodology, Writing – review & editing

Affiliation: Arthritis Research Canada, Vancouver, British Columbia, Canada

Natalie McCormick

Roles: Methodology, Writing – review & editing

Affiliations: Arthritis Research Canada, Vancouver, British Columbia, Canada, Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America

ORICD: https://orcid.org/0000-0002-4147-8348

Hui Xie

Roles: Methodology, Writing – review & editing

Affiliations: Arthritis Research Canada, Vancouver, British Columbia, Canada, Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada

Hyon K. Choi

Roles: Methodology, Writing – review & editing

Affiliations: Arthritis Research Canada, Vancouver, British Columbia, Canada, Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States of America

J. Antonio Aviña-Zubieta

Roles: Conceptualization, Funding acquisition, Methodology, Resources, Supervision, Writing – review & editing

E-mail: [email protected]

Affiliations: Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada, Arthritis Research Canada, Vancouver, British Columbia, Canada

ORICD: https://orcid.org/0000-0001-5526-663X

[/RAW_REF_TEXT]

[/RAW_REF_TEXT]

[/RAW_REF_TEXT]

[/RAW_REF_TEXT]

References

1. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: A meta-analysis of observational studies. Arthritis Care Res 2008;59(12):1690–7. pmid:19035419

2. Liu L, Cui S, Liu M, Huo X, Zhang G, Wang N. Psoriasis Increased the Risk of Adverse Cardiovascular Outcomes: A New Systematic Review and Meta-Analysis of Cohort Study. Front Cardiovasc Med 2022;9:829709. pmid:35402553

3. Haroon NN, Paterson JM, Li P, Inman RD, Haroon N. Patients With Ankylosing Spondylitis Have Increased Cardiovascular and Cerebrovascular Mortality. Ann Intern Med 2015;163(6):409–16. pmid:26258401

4. Bartels CM, Buhr KA, Goldberg JW, Bell CL, Visekruna M, Nekkanti S, et al. Mortality and Cardiovascular Burden of Systemic Lupus Erythematosus in a US Population-based Cohort. J Rheumatol 2014;41(4):680. pmid:24532834

5. Wallace ZS, Fu X, Harkness T, Stone JH, Zhang Y, Choi H. All-cause and cause-specific mortality in ANCA-associated vasculitis: overall and according to ANCA type. Rheumatology (Oxford) 2020;59(9):2308–15. pmid:31846030

6. Uddhammar A, Eriksson AL, Nyström L, Stenling R, Rantapää-Dahlqvist S. Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol 2002;29(4):737. pmid:11950015

7. Versini M, Jeandel PY, Rosenthal E, Shoenfeld Y. Obesity in autoimmune diseases: Not a passive bystander. Autoimmun Rev 2014;13(9):981–1000. pmid:25092612

8. Jiang MY, Hwang JC, Feng IJ. Impact of Diabetes Mellitus on the Risk of End-Stage Renal Disease in Patients with Systemic Lupus Erythematosus. Sci Rep 2018;8(1):6008. pmid:29662119

9. Yun H, Xie F, Chen L, Yang S, Ferri L, Alemao E, et al. Evaluation of the Effect of Diabetes on Rheumatoid Arthritis–related Outcomes in an Electronic Health Record–based Rheumatology Registry. J Rheumatol 2020;48(7):992–1001. pmid:33262304

10. Rohm TV, Meier DT, Olefsky JM, Donath MY. Inflammation in obesity, diabetes, and related disorders. Immunity 2022;55(1):31–55. pmid:35021057

11. Poznyak A, Grechko AV, Poggio P, Myasoedova VA, Alfieri V, Orekhov AN. The Diabetes Mellitus–Atherosclerosis Connection: The Role of Lipid and Glucose Metabolism and Chronic Inflammation. Int J Mol Sci 2020;21(5):1835. pmid:32155866

12. Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives. Eur Cardiol 2019;14(1):50–9. pmid:31131037

13. Kanie T, Mizuno A, Takaoka Y, Suzuki T, Yoneoka D, Nishikawa Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev 2021;10(10):CD013650. pmid:34693515

14. Arturi F, Succurro E, Miceli S, Cloro C, Ruffo M, Maio R, et al. Liraglutide improves cardiac function in patients with type 2 diabetes and chronic heart failure. Endocrine 2017;57(3):464–73. pmid:27830456

15. Wang Q, Wang D, Cheng A, Sun FY, Li Z. Comparison between the effects of sitagliptin and liraglutide on blood glucose and cognitive function of patients with both type 2 diabetes mellitus and post-stroke mild cognitive impairment. Int J Clin Exp Med 2020;13(2):1219–27.

16. Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail 2017;19(1):69–77. pmid:27790809

17. Karacabeyli D, Lacaille D. Glucagon-Like Peptide 1 Receptor Agonists in Patients With Inflammatory Arthritis or Psoriasis: A Scoping Review. J Clin Rheumatol 2024;30(1):26–31. pmid:36870080

18. Gilbert MP, Pratley RE. GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials. Front Endocrinol 2020;11:178. pmid:32308645

19. BC Gov News. PharmaCare expands diabetes, heart failure, blood clot drugs coverage. Ministry of Health. 2023 [cited 2023 Nov 17]. Available from: https://news.gov.bc.ca/releases/2023HLTH0001-000004

20. Stats BC. 2021 Sub-Provincial Population Estimates Highlights [online]. https://www2.gov.bc.ca/assets/gov/data/statistics/people-population-community/population/pop_subprovincial_population_highlights.pdf (accessed November 24, 2022).

21. BC Ministry of Health. Medical Services Plan (MSP) Payment Information File. V2. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

22. BC Ministry of Health. Discharge Abstracts Database (Hospital Separations). V2. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

23. BC Ministry of Health. National Ambulatory Care Reporting System. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

24. BC Ministry of Health. PharmaNet. V2. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

25. BC Ministry of Health. Vital Events Deaths. Population Data BC [publisher]. Data Extract [dataset]. http://www.popdata.bc.ca/data (accessed November 10, 2022).

26. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: A population study. Arthritis Rheum 2005;53(2):241–8. pmid:15818655

27. Leong A, Dasgupta K, Bernatsky S, Lacaille D, Avina-Zubieta A, Rahme E. Systematic review and meta-analysis of validation studies on a diabetes case definition from health administrative records. PloS One 2013;8(10):e75256. pmid:24130696

28. Arkema EV, Jönsen A, Rönnblom L, Svenungsson E, Sjöwall C, Simard JF. Case definitions in Swedish register data to identify systemic lupus erythematosus. BMJ Open 2016;6(1):e007769. pmid:26729375

29. Weng X, Liu L, Barcellos LF, Allison JE, Herrinton LJ. Clustering of Inflammatory Bowel Disease With Immune Mediated Diseases Among Members of a Northern California-Managed Care Organization. Am J Gastroenterol 2007;102(7):1429–35. pmid:17437504

30. Asgari MM, Wu JJ, Gelfand JM, Salman C, Curtis JR, Harrold LR, et al. Validity of diagnostic codes and prevalence of psoriasis and psoriatic arthritis in a managed care population, 1996–2009. Pharmacoepidemiol Drug Saf 2013;22(8):842–9. pmid:23637091

31. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PloS One 2014;9(3):e92286. pmid:24682186

32. McCormick N, Bhole V, Lacaille D, Avina-Zubieta JA. Validity of Diagnostic Codes for Acute Stroke in Administrative Databases: A Systematic Review. PloS One 2015;10(8):e0135834. pmid:26292280

33. Romano PS, Roos LL, Jollis JG. Presentation adapting a clinical comorbidity index for use with ICD-9-CM administrative data: Differing perspectives. J Clin Epidemiol 1993;46(10):1075–9.

34. Health Canada. Product Information—Victoza [Online]. 2022. Available from: https://health-products.canada.ca/dpd-bdpp/info.do?lang=en&code=83627#fn1 (accessed 2022 Dec 14).

35. Li F, Thomas LE, Li F. Addressing Extreme Propensity Scores via the Overlap Weights. Am J Epidemiol 2019;188(1):250–7. pmid:30189042

36. Li F, Morgan KL, Zaslavsky AM. Balancing Covariates via Propensity Score Weighting. J Am Stat Assoc 2018;113(521):390–400.

37. Austin PC, Stuart EA. Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 2015;34(28):3661–79. pmid:26238958

38. Fine JP, Gray RJ. A Proportional Hazards Model for the Subdistribution of a Competing Risk. J Am Stat Assoc 1999;94(446):496–509.

39. VanderWeele TJ, Ding P. Sensitivity Analysis in Observational Research: Introducing the E-Value. Ann Intern Med 2017;167(4):268–74. pmid:28693043

40. Elm E von Altman DG, Egger M Pocock SJ, Gøtzsche PC Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007;335(7624):806. pmid:17947786

41. Solomon DH, Reed GW, Kremer JM, Curtis JR, Farkouh ME, Harrold LR, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol 2015;67(6):1449–55. pmid:25776112

42. Du X, Zhang H, Zhang W, Wang Q, Wang W, Ge G, et al. The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. Int Immunopharmacol 2019;75:105732. pmid:31336333

43. Zheng W, Pan H, Wei L, Gao F, Lin X. Dulaglutide mitigates inflammatory response in fibroblast-like synoviocytes. Int Immunopharmacol 2019;74:105649. pmid:31185450

44. Tao Y, Ge G, Wang Q, Wang W, Zhang W, Bai J, et al. Exenatide ameliorates inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes. IUBMB Life 2019;71(7):969–77. pmid:30897288

45. Yang J, Wang Z, Zhang X. GLP-1 receptor agonist impairs keratinocytes inflammatory signals by activating AMPK. Exp Mol Pathol 2019;107:124–8. pmid:30776356

46. Al-Dwairi A, Alqudah TE, Al-Shboul O, Alqudah M, Mustafa AG, Alfaqih MA. Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro. J Inflamm Res 2018;11:95–109. pmid:29593427

47. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017;2:17023. pmid:29158945

48. Salminen A, Hyttinen JMT, Kaarniranta K. AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan. J Mol Med (Berl) 2011;89(7):667–76. pmid:21431325

49. Fiordelisi A, Iaccarino G, Morisco C, Coscioni E, Sorriento D. NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases. Int J Mol Sci 2019;20(7):1599. pmid:30935055

50. Suissa K, Schneeweiss S, Lin KJ, Brill G, Kim SC, Patorno E. Validation of obesity-related diagnosis codes in claims data. Diabetes Obes Metab 2021;23(12):2623–31. pmid:34338404

51. Powell-Wiley TM, Poirier P, Burke LE, Després JP, Gordon-Larsen P, Lavie CJ, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation 2021;143(21):e984–1010. pmid:33882682